Common cold
Conditions
Interventions
Group A (Control): Placebo + Symptomatic treatment Group B (Study): 300 mg of French oregano + Symptomatic treatment Group C (Study): 600 mg of French oregano + Symptomatic treatment The French oregan
Sponsors
Drug Research and Development Center (CIDEM)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patient bigger than 18 years of age. 2. Written consent of patient 3. Patient with cough and expectoration of less than 14 days. 4. Negative Leucogram, with or without altered lymphocytes.
Exclusion criteria
Exclusion criteria: 1. Pregnancy or breastfeeding. 2. Not meet any criteria for inclusion. 3. Patients with ERC Chronic disorders: Asthma, EPOC, bronquiectasias 4. Ingestion of medications: steroids, antipsicóticos habitually. 5. Ingestion of antibiotics, broncodilatadores, during one previous month. 6. Cough originated by adverse effect to the IECA or foreign bodies. 7. Patients with presence of sputum purulento, serous or bloody. 8. Patients with presence of humid stertors in the physical test. 9. Patients with decompensated Chronic disorders not transmissible. 10.Patients with any neurological or systemic disorder affecting the nervous system. 11.HIV.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Frequency of the cough in 24 hours (0 - Non cough, 1 - of 1 to 4 times, 2 - of 5 to 10 times, 3 - of 11 at 15 times and 4 - more than 15 times). Measuring time: 3, 7 and 15 days. Intensity of the cough in 24 hours (Slight: less than 5 accesses of cough and it can accompany of expectoration. Moderate: More than 5 accesses of cough and less than 10. Severe: More than 10 accesses of cough). Measuring time: 3, 7 and 15 days. Expectoration presence. (Yes/No).Measuring time: 3, 7 and 15 days. | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events (Description, Intensity, Duration). Measuring time: 15 days. Description of the adverse event (Name) Intensity of the adverse event (Light, Moderate, Severe) Duration of the adverse event. (differs of date among the beginning and final of the event) | — |
Countries
Cuba
Contacts
Public ContactJorge Rodriguez Chanfrau
Drug Research and Development Center CIDEM)
Outcome results
None listed